Dyne Therapeutics (DYN) Competitors

$17.61 +0.07 (+0.40%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$17.62 +0.02 (+0.09%)

As of 05/8/2026 04:40 PM Eastern

DYN vs. RDY, ELAN, ARWR, PRAX, and AXSM

Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Praxis Precision Medicines (PRAX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.81B	2.90	$663M	$0.77	17.21
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A

Dr. Reddy's Laboratories has a net margin of 16.41% compared to Dyne Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 15.89% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	16.41%	15.89%	10.73%
Dyne Therapeutics	N/A	-61.46%	-50.94%

In the previous week, Dyne Therapeutics had 9 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Dyne Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Dyne Therapeutics' score of 0.46 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories currently has a consensus price target of $16.90, suggesting a potential upside of 27.55%. Dyne Therapeutics has a consensus price target of $35.14, suggesting a potential upside of 99.56%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Summary

Dr. Reddy's Laboratories and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Elanco Animal Health has higher revenue and earnings than Dyne Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.49	-$232M	-$0.50	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A

Dyne Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Dyne Therapeutics	N/A	-61.46%	-50.94%

In the previous week, Elanco Animal Health had 15 more articles in the media than Dyne Therapeutics. MarketBeat recorded 26 mentions for Elanco Animal Health and 11 mentions for Dyne Therapeutics. Elanco Animal Health's average media sentiment score of 0.59 beat Dyne Therapeutics' score of 0.46 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Elanco Animal Health currently has a consensus price target of $28.20, suggesting a potential upside of 19.82%. Dyne Therapeutics has a consensus price target of $35.14, suggesting a potential upside of 99.56%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Summary

Elanco Animal Health beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Dyne Therapeutics (NASDAQ:DYN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A
Arrowhead Pharmaceuticals	$829.45M	12.27	-$1.63M	$1.53	47.51

Dyne Therapeutics currently has a consensus price target of $35.14, suggesting a potential upside of 99.56%. Arrowhead Pharmaceuticals has a consensus price target of $84.90, suggesting a potential upside of 16.79%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Dyne Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dyne Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -56.92% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
Arrowhead Pharmaceuticals	-48.38%	-56.92%	-20.66%

Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Dyne Therapeutics. MarketBeat recorded 19 mentions for Arrowhead Pharmaceuticals and 11 mentions for Dyne Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.79 beat Dyne Therapeutics' score of 0.46 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dyne Therapeutics and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Dyne Therapeutics (NASDAQ:DYN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Dyne Therapeutics currently has a consensus price target of $35.14, suggesting a potential upside of 99.56%. Praxis Precision Medicines has a consensus price target of $591.83, suggesting a potential upside of 79.33%. Given Dyne Therapeutics' higher possible upside, research analysts plainly believe Dyne Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.00

Praxis Precision Medicines' return on equity of -60.25% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
Praxis Precision Medicines	N/A	-60.25%	-54.81%

In the previous week, Praxis Precision Medicines had 6 more articles in the media than Dyne Therapeutics. MarketBeat recorded 17 mentions for Praxis Precision Medicines and 11 mentions for Dyne Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.70 beat Dyne Therapeutics' score of 0.46 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Praxis Precision Medicines has higher revenue and earnings than Dyne Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A
Praxis Precision Medicines	$8.55M	1,075.75	-$303.27M	-$13.37	N/A

Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500.

Summary

Praxis Precision Medicines beats Dyne Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 15.59%. Dyne Therapeutics has a consensus price target of $35.14, suggesting a potential upside of 99.56%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Dyne Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Dyne Therapeutics' return on equity of -61.46% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Dyne Therapeutics	N/A	-61.46%	-50.94%

In the previous week, Axsome Therapeutics had 39 more articles in the media than Dyne Therapeutics. MarketBeat recorded 50 mentions for Axsome Therapeutics and 11 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.46 beat Axsome Therapeutics' score of 0.25 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	15 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Dyne Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Axsome Therapeutics has higher revenue and earnings than Dyne Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.52	-$183.17M	-$3.73	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.90B	$3.07B	$6.25B	$12.12B
Dividend Yield	N/A	1.93%	2.78%	5.20%
P/E Ratio	-4.97	18.14	20.64	25.39
Price / Sales	N/A	287.18	534.02	75.96
Price / Cash	N/A	56.08	43.29	53.47
Price / Book	2.59	4.27	9.98	6.81
Net Income	-$446.21M	$72.19M	$3.54B	$333.04M
7 Day Performance	1.27%	24.89%	3.50%	3.17%
1 Month Performance	-9.04%	3.25%	4.17%	7.14%
1 Year Performance	53.93%	47.14%	41.86%	41.22%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	2.9461 of 5 stars	$17.61 +0.4%	$35.14 +99.6%	N/A	$2.90B	N/A	N/A	100	News Coverage Upcoming Earnings Insider Trade
RDY Dr. Reddy's Laboratories	3.6901 of 5 stars	$13.97 +2.2%	$16.90 +21.0%	N/A	$11.41B	$3.81B	18.14	27,811	Upcoming Earnings
ELAN Elanco Animal Health	3.5854 of 5 stars	$22.08 -3.0%	$27.90 +26.4%	N/A	$11.31B	$4.72B	N/A	9,400	Trending News Earnings Report Analyst Forecast
ARWR Arrowhead Pharmaceuticals	3.1188 of 5 stars	$73.60 -0.4%	$83.78 +13.8%	N/A	$10.35B	$829.45M	48.10	400	News Coverage Earnings Report Analyst Forecast
PRAX Praxis Precision Medicines	3.3425 of 5 stars	$330.99 -4.0%	$590.78 +78.5%	N/A	$9.60B	$8.55M	N/A	110	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ELAN, ARWR, PRAX, and AXSM

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ELAN, ARWR, PRAX, and AXSM

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Which has better valuation and earnings, RDY or DYN?

Is RDY or DYN more profitable?

Does the media favor RDY or DYN?

Which has more volatility and risk, RDY or DYN?

Do insiders & institutionals hold more shares of RDY or DYN?

Do analysts rate RDY or DYN?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Which has preferable valuation & earnings, ELAN or DYN?

Is ELAN or DYN more profitable?

Does the media refer more to ELAN or DYN?

Which has more risk and volatility, ELAN or DYN?

Do institutionals & insiders hold more shares of ELAN or DYN?

Do analysts rate ELAN or DYN?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Which has higher earnings & valuation, DYN or ARWR?

Do analysts rate DYN or ARWR?

Do insiders and institutionals hold more shares of DYN or ARWR?

Is DYN or ARWR more profitable?

Which has more volatility & risk, DYN or ARWR?

Does the media refer more to DYN or ARWR?

Summary

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Do analysts rate DYN or PRAX?

Is DYN or PRAX more profitable?

Does the media refer more to DYN or PRAX?

Do insiders and institutionals hold more shares of DYN or PRAX?

Which has higher earnings & valuation, DYN or PRAX?

Which has more volatility & risk, DYN or PRAX?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Do analysts prefer AXSM or DYN?

Is AXSM or DYN more profitable?

Does the media prefer AXSM or DYN?

Which has more volatility & risk, AXSM or DYN?

Which has better earnings & valuation, AXSM or DYN?

Do institutionals and insiders hold more shares of AXSM or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools